We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old (KL4-AHRF-01)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00578734
First Posted: December 21, 2007
Last Update Posted: May 3, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Windtree Therapeutics
Results First Submitted: April 2, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Acute Hypoxemic Respiratory Failure
Interventions: Drug: Lucinactant
Other: Sham Comparator

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were enrolled at 24 hospitals in the United States and Chile from 04 June, 2007 to 23 March, 2010. Last subject's last visit occurred on 05 April, 2010.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Lucinactant KL₄Surfactant (lucinactant) endotracheal instillation
Sham Air Sham air (placebo) instillation

Participant Flow:   Overall Study
    Lucinactant   Sham Air
STARTED   84   81 
COMPLETED   84   81 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Lucinactant KL₄Surfactant (lucinactant) endotracheal instillation
Sham Air Sham air (placebo) instillation
Total Total of all reporting groups

Baseline Measures
   Lucinactant   Sham Air   Total 
Overall Participants Analyzed 
[Units: Participants]
 84   81   165 
Age 
[Units: Participants]
     
<=18 years   84   81   165 
Between 18 and 65 years   0   0   0 
>=65 years   0   0   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 0.44  (0.43)   0.45  (0.43)   0.45  (0.43) 
Gender 
[Units: Participants]
     
Female   29   27   56 
Male   55   54   109 
Region of Enrollment 
[Units: Participants]
     
United States   28   27   55 
Chile   56   54   110 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Duration of Mechanical Ventilation Through 14 Days   [ Time Frame: Up to 14 Days ]

2.  Secondary:   Ventilator-free Days; Duration of Days on Oxygen, Intensive Care Unit (ICU) Stay, and Hospitalization Through 14 Days   [ Time Frame: Up to 14 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Dr. Neal J. Thomas
Organization: Penn State Children's Hospital
phone: 717-531-5337
e-mail: nthomas@hmc.psu.edu


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Windtree Therapeutics
ClinicalTrials.gov Identifier: NCT00578734     History of Changes
Other Study ID Numbers: KL4-AHRF-01
First Submitted: December 19, 2007
First Posted: December 21, 2007
Results First Submitted: April 2, 2012
Results First Posted: April 27, 2012
Last Update Posted: May 3, 2012